Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study

Hezzell, M J and Boswood, A and Lopez-Alvarez, J and Lotter, N S and Elliott, J (2017) Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. Journal of Veterinary Cardiology, 19 (4). pp. 325-328.

[img]
Preview
Text
10924.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factors for poorer prognosis will decrease the rate of disease progression. The aim was to provide pilot data to evaluate preliminary effects and sample size calculation for a definitive clinical trial.

Actions (Repository Editors)

View Item View Item